Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants

torstai 14. kesäkuuta 2018 päivittänyt: GlaxoSmithKline

A Phase 3b, Open-Label, Randomized, Multicenter Study to Assess the Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants

The purpose of this trial is to evaluate the immunogenicity, the safety and the tolerability of rMenB+OMV NZ and MenACWY vaccines in healthy infants, when concomitantly administered at 3, 5, 7 and 13 months of age, compared to either alone.

Tutkimuksen yleiskatsaus

Tila

Valmis

Ehdot

Interventio / Hoito

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

750

Vaihe

  • Vaihe 3

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

  • Argentiina
      • Buenos Aires, Argentiina, C1425EFD
        • GSK Investigational Site
      • Buenos Aires, Argentiina, C1425DEM
        • GSK Investigational Site
      • Cordoba, Argentiina, X5000JRD
        • GSK Investigational Site
  • Meksiko
      • Mexico City, Meksiko, 06760
        • GSK Investigational Site
      • Mexico City, Meksiko, 04530
        • GSK Investigational Site
      • Mexico City, Meksiko, 06400
        • GSK Investigational Site
      • Morelia, Meksiko, 58070
        • GSK Investigational Site

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

2 kuukautta - 3 kuukautta (Lapsi)

Hyväksyy terveitä vapaaehtoisia

Joo

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  1. Healthy 3-month old infants (85-119 days, inclusive) at time of Visit 1 whose parents/legal guardians have given written informed consent after the nature of the study has been explained.
  2. Available for all the visits scheduled in the study.
  3. In good health as determined by medical history, physical examination and clinical judgment of the investigator.

Exclusion Criteria:

  1. History of any previous immunization with a meningococcal vaccine or vaccine containing meningococcal antigen(s) at the time of enrollment.
  2. Previous known or suspected disease caused by N. meningitidis.
  3. Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis infection or colonization.
  4. History of severe allergic reaction after previous vaccinations, or hypersensitivity to any component of the vaccine.

  5. Known or suspected autoimmune disease or impairment/alteration of the immune system resulting from, for ex-ample:

    • Chronic administration of immunosuppressants or other immune-modifying drugs since birth (3 months prior). (For corticosteroids, this means prednisone, or equivalent, ≥ 0.5 mg/kg/day or ≥ 10 mcg/day for children below 2 years. Inhaled and topical steroids are allowed),
    • Immune deficiency disorder, or known HIV infection.
  6. Receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation since birth.
  7. History of any progressive or severe neurologic disorder, or seizure disorder or Guillan Barré syndrome (exception: one self-limited febrile seizure is acceptable).
  8. History of any bleeding disorder considered as a contraindication to intramuscular injection or blood draw.
  9. Child's parent(s) or legal guardian(s) are not able to comprehend and to follow all required study procedures for the whole period of the study.
  10. Receipt of any investigational or non-registered product since birth (3 month prior) or are expected to receive during the study period.
  11. Family members or household members of site research staff.
  12. Any clinically-significant chronic or progressive disease according to judgment of the investigator (pulmonary, cardiovascular, renal, hepatic or endocrine functional abnormality) or a congenital anomaly/known cytogenic disorder (e.g., Down's syndrome).
  13. History or any illness/condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Ennaltaehkäisy
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: rMenB+ACWY
Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
Biologinen: Meningococcal group B Vaccine, rMenB+OMV NZ
4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
Muut nimet:
  • Bexsero®
Biologinen: Meningococcal ACWY Conjugate Vaccine, MenACWY
4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
Muut nimet:
  • Menveo®
Active Comparator: rMENB
Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
Biologinen: Meningococcal group B Vaccine, rMenB+OMV NZ
4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
Muut nimet:
  • Bexsero®
Active Comparator: MenACWY
Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
Biologinen: Meningococcal ACWY Conjugate Vaccine, MenACWY
4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
Muut nimet:
  • Menveo®

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) Against Each of the Serogroup B Indicator Strains
Aikaikkuna: At Day 331 (one month after the fourth vaccination)

Human serum bactericidal activity (hSBA) titers against each of the serogroup B indicator strains-H44/76,5/99,NZ98/254 & M10713 after receiving 4 doses of rMenB+OMV NZ / MenACWY vaccines, concomitantly administered, versus corresponding response in subjects who received rMenB+OMV NZ administered alone, were presented in terms of vaccine group specific geometric mean titers (GMTs).

This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.
At Day 331 (one month after the fourth vaccination)
hSBA Geometric Mean Titers (GMTs) Against Each of the Serogroups A, C, W-135 and Y
Aikaikkuna: At Day 331 (one month after the fourth vaccination)

hSBA titers against N. meningitidis serogroups A, C, W-135 and Y after receiving four doses of either rMenB+OMV NZ / MenACWY concomitantly administered versus corresponding response in subjects who received MenACWY administered alone were presented in terms of vaccine group specific GMTs.

This outcome measure applies to only rMenB+ACWY and MenACWY groups as the serogroups A,C,W-135 & Y were assessed only for these two groups.
At Day 331 (one month after the fourth vaccination)

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
hSBA Geometric Mean Titers Against Each of the Serogroup B Indicator Strains.
Aikaikkuna: At Day 1

hSBA GMTs against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 & M10713 at baseline (Day 1).

This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B strains were assessed only for these two groups.
At Day 1
hSBA Geometric Mean Titers Against Each of the Serogroup B Indicator Strains.
Aikaikkuna: At Day 151 (one month after the third vaccination)

hSBA GMTs against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 & M10713 at one month after the third vaccination (Day 151).

This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B strains were assessed only for these two groups.
At Day 151 (one month after the third vaccination)
hSBA Geometric Mean Titers Against Each of the Serogroup B Indicator Strains.
Aikaikkuna: At Day 301 (before the fourth vaccination)

hSBA GMTs against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 & M10713 before the fourth vaccination (Day 301).

This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B strains were assessed only for these two groups.
At Day 301 (before the fourth vaccination)
hSBA Geometric Mean Titers Against Each of the Serogroup B Indicator Strains.
Aikaikkuna: At Day 331 (one month after the fourth vaccination)

hSBA GMTs against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 & M10713 at one month after the fourth vaccination (Day 331).

This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B strains were assessed only for these two groups.
At Day 331 (one month after the fourth vaccination)
hSBA Geometric Mean Titers Against Each of the Serogroups A,C,W-135 & Y.
Aikaikkuna: At Day 1

hSBA GMTs against each of the N. meningitidis serogroups A, C, W-135, Y at baseline (Day 1).

This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups A,C,W-135 & Y were assessed only for these two groups.
At Day 1
hSBA Geometric Mean Titers Against Each of the Serogroups A, C, W-135 and Y
Aikaikkuna: At Day 151 (one month after the third vaccination)

hSBA GMTs against each of the N. meningitidis serogroups A, C, W-135, Y at one month after the third vaccination (Day 151).

This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups A,C,W-135 & Y were assessed only for these two groups.
At Day 151 (one month after the third vaccination)
hSBA Geometric Mean Titers Against Each of the Serogroups A,C,W-135 & Y.
Aikaikkuna: At Day 301 (before the fourth vaccination)

hSBA GMTs against each of the N. meningitidis serogroups A, C, W-135, Y before the fourth vaccination (Day 301).

This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups A,C,W-135 & Y were assessed only for these two groups.
At Day 301 (before the fourth vaccination)
hSBA Geometric Mean Titers Against Each of the Serogroups A,C,W-135 & Y.
Aikaikkuna: At Day 331 (one month after the fourth vaccination)

hSBA GMTs against each of the N.meningitidis serogroups A, C, W-135, Y at one month after the fourth vaccination (Day 331).

This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups A,C,W-135 & Y were assessed only for these two groups.
At Day 331 (one month after the fourth vaccination)
Percentage of Subjects With hSBA Titers ≥1:5 Against Each of the Serogroup B Indicator Strains
Aikaikkuna: At Day 1

Percentage of subjects with hSBA titers≥ 1:5 against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 & M10713 before the first vaccination (Day 1).

This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B strains were assessed only for these two groups.
At Day 1
Percentage of Subjects With hSBA Titers ≥1:5 Against Each of the Serogroup B Indicator Strains
Aikaikkuna: At Day 151 (one month after the third vaccination)

Percentage of subjects with hSBA titers ≥ 1:5 against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 & M10713 one month after the third vaccination (Day 151).

This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.
At Day 151 (one month after the third vaccination)
Percentage of Subjects With hSBA Titers ≥1:5 Against Each of the Serogroup B Strains.
Aikaikkuna: At Day 301 (before the fourth vaccination)

Percentage of subjects with hSBA titers ≥ 1:5 against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 & M10713 before the fourth vaccination (Day 301).

This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.
At Day 301 (before the fourth vaccination)
Percentage of Subjects With hSBA Titers ≥1:5 Against Each of the Serogroup B Strains.
Aikaikkuna: At Day 331 (One month after the fourth vaccination)

Percentage of subjects with hSBA titers ≥ 1:5 against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 & M10713 one month after the fourth vaccination (Day 331).

This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.
At Day 331 (One month after the fourth vaccination)
Percentage of Subjects With hSBA Titers ≥1:8 Against Each of the Serogroup B Indicator Strains
Aikaikkuna: At Day 1

Percentage of subjects with hSBA titers ≥ 1:8 against each of the N. meningitidis serogroup B indicator strains at baseline (Day 1).

This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.
At Day 1
Percentage of Subjects With hSBA Titers ≥1:8 Against Each of the Serogroup B Indicator Strains
Aikaikkuna: At Day 151 (one month after the third vaccination)

Percentage of subjects with hSBA titers ≥ 1:8 against each of the N. meningitidis serogroup B indicator strains at one month after third vaccination (Day 151).

This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.
At Day 151 (one month after the third vaccination)
Percentage of Subjects With hSBA Titers ≥1:8 Against Each of the Serogroup B Indicator Strains
Aikaikkuna: At Day 301 (before the fourth vaccination)

Percentage of subjects with hSBA titers ≥ 1:8 against each of the N. meningitidis serogroup B indicator strains before the fourth vaccination (Day 301).

This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.
At Day 301 (before the fourth vaccination)
Percentage of Subjects With hSBA Titers≥1:8 Against Each of the Serogroup B Indicator Strains
Aikaikkuna: At Day 331 (one month after the fourth vaccination)

Percentage of subjects with hSBA titers≥ 1:8 against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 & M10713 at one month after the fourth vaccination (Day 331).

This outcome measure applies to only rMenB+ACWY and rMenB groups as the serogroup B indicator strains were assessed only for these two groups.
At Day 331 (one month after the fourth vaccination)
Percentage of Subjects With hSBA Titers ≥1:4 Against Each of the Serogroups A, C, W-135 and Y
Aikaikkuna: At Day 1

Percentage of subjects with hSBA titers≥ 1:4 against each of the N. meningitidis serogroups A, C, W-135 and Y before the first vaccination (Day 1).

This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.
At Day 1
Percentage of Subjects With hSBA Titers≥1:4 Against Each of the Serogroups A, C, W-135 and Y
Aikaikkuna: At Day 151 (one month after the third vaccination)
Percentage of subjects with hSBA titers≥ 1:4 against each of the N. meningitidis serogroups A, C, W-135 and Y at one month after the third vaccination (Day 151). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.
At Day 151 (one month after the third vaccination)
Percentage of Subjects With hSBA Titers≥1:4 Against Each of the Serogroups A, C, W-135 and Y
Aikaikkuna: At Day 301 (before the fourth vaccination)

Percentage of subjects with hSBA titers≥ 1:4 against each of the N. meningitidis serogroups A, C, W-135 and Y before the fourth vaccination (Day 301).

This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.
At Day 301 (before the fourth vaccination)
Percentage of Subjects With hSBA Titers≥1:4 Against Each of the Serogroups A, C, W-135 and Y
Aikaikkuna: At Day 331 (one month after the fourth vaccination)
Percentage of subjects with hSBA titers≥ 1:4 against each of the N. meningitidis serogroups A, C, W-135 and Y at one month after the fourth vaccination (Day 331). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.
At Day 331 (one month after the fourth vaccination)
Within-subject Geometric Mean Ratios (GMRs) Against Each of the Serogroup B Indicator Strains
Aikaikkuna: At Day 331 (one month after fourth vaccination)
Geometric Mean Ratios(GMRs) of GMTs against each of the serogroup B indicator strains- H44/76, 5/99, N98/254 & M10713 were calculated at one month after the fourth vaccination (Day 331) versus pre fourth vaccination(Day 301).
At Day 331 (one month after fourth vaccination)
Within-subject Geometric Mean Ratios (GMRs) Against Each of Serogroups A, C, W-135 and Y
Aikaikkuna: At Day 331 (one month after the fourth vaccination)
Geometric Mean Ratios(GMRs) of GMTs against each of the serogroups A,C,W-135 & Y were calculated at one month after the fourth vaccination (Day 331) versus pre fourth vaccination (Day 301).
At Day 331 (one month after the fourth vaccination)
Percentage of Subjects With Four-fold Increases in hSBA Titers Against Each of the Serogroup B Indicator Strains
Aikaikkuna: At Day 331 (one month after the fourth vaccination)

Percentage of subjects with four-fold increase in hSBA titers against each of the N. meningitidis serogroup B indicator strains-H44/76,5/99,NZ98/254 & M10713 at one month after the fourth vaccination (Day 331) over pre-fourth vaccination (Day 301).

This outcome measure applies to only groups rMenB+ACWY and rMenB as the serogroup B indicator strains were assessed only for these two groups.

For serogroup B strains, 4-fold increase in titers was defined as post 4th vaccination titer ≥8 (if pre 4th vaccination titer was <2) or post 4th vaccination titer ≥ 4 x pre 4th vaccination titer (if pre 4th vaccination titer was ≥2).
At Day 331 (one month after the fourth vaccination)
Percentage of Subjects With Four-fold Increases in hSBA Titers Against Each of the Serogroups A, C, W-135 and Y
Aikaikkuna: At Day 331 (one month after the fourth vaccination)

Percentages of subjects with four-fold increases in hSBA against each of the N. meningitidis serogroups A,C,W & Y at one month after the fourth vaccination (Day 331) over pre-fourth vaccination(Day 301).

This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.

For serogroups A, C, W and Y, 4-fold increase in titers was defined as post 4th vaccination titer ≥16 (if pre 4th vaccination titer was <4) or post 4th vaccination titer ≥ 4 x pre 4th vaccination titer (if pre 4th vaccination titer was ≥4).
At Day 331 (one month after the fourth vaccination)
Percentage of Subjects With hSBA Titers≥1:8 Against Each of the Serogroups A, C, W-135 and Y
Aikaikkuna: At Day 1

Percentage of subjects with hSBA titers≥ 1:8 against each of the N. meningitidis serogroups A, C, W-135 and Y at baseline (Day 1).

This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.
At Day 1
Percentage of Subjects With hSBA Titers≥1:8 Against Each of the Serogroups A, C, W-135 and Y
Aikaikkuna: At Day 151 (one month before the third vaccination)

Percentage of subjects with hSBA titers≥ 1:8 against each of the N. meningitidis serogroups A, C, W-135 & Y at one month after the third vaccination (Day 151).

This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.
At Day 151 (one month before the third vaccination)
Percentage of Subjects With hSBA Titers≥1:8 Against Each of the Serogroups A, C, W-135 and Y
Aikaikkuna: At Day 301 (before the fourth vaccination)
Percentage of subjects with hSBA titers≥ 1:8 against each of the N. meningitidis serogroups A, C, W-135 & Y before the fourth vaccination (Day 301). This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.
At Day 301 (before the fourth vaccination)
Percentage of Subjects With hSBA Titers≥1:8 Against Each of the Serogroups A, C, W-135 and Y
Aikaikkuna: At Day 331 (one month after the fourth vaccination)

Percentage of subjects with hSBA titers≥ 1:8 against each of the N. meningitidis serogroups A, C, W-135 & Y at one month after the fourth vaccination (Day 331).

This outcome measure applies to only rMenB+ACWY and MENACWY groups as the serogroups were assessed only for these two groups.
At Day 331 (one month after the fourth vaccination)
Number of Subjects With Solicited Local and Systemic Adverse Events (AEs)
Aikaikkuna: From Day 1 (6 hours) to Day 7 after each vaccination (Days 1, 61, 121 and 301)
Number of subjects with solicited local and systemic AEs during the 7 days (including the day of vaccination) after any vaccination
From Day 1 (6 hours) to Day 7 after each vaccination (Days 1, 61, 121 and 301)
Number of Subjects With Unsolicited Adverse Events
Aikaikkuna: From Day 1 to Day 7 after each vaccination (Days 1, 61, 121 and 301)
An unsolicited adverse event (AE) is defined as any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product at any dose that does not necessarily have to have a causal relationship with this treatment.
From Day 1 to Day 7 after each vaccination (Days 1, 61, 121 and 301)
Number of Subjects With SAEs, AEs Leading to Withdrawal and Medically Attended AEs (MAEs)
Aikaikkuna: Throughout the whole study period (from Day 1 upto Day 331)
A serious adverse event is any untoward medical occurrence that at any dose results in death/ is life threatening/requires prolonged hospitalization/Persistent or significant disability/incapacity/congenital anomaly/or birth defect.
Throughout the whole study period (from Day 1 upto Day 331)

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

GlaxoSmithKline

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Torstai 5. kesäkuuta 2014

Ensisijainen valmistuminen (Todellinen)

Perjantai 14. lokakuuta 2016

Opintojen valmistuminen (Todellinen)

Perjantai 14. lokakuuta 2016

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Perjantai 14. helmikuuta 2014

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Torstai 3. huhtikuuta 2014

Ensimmäinen Lähetetty (Arvio)

Tiistai 8. huhtikuuta 2014

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Keskiviikko 22. elokuuta 2018

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Torstai 14. kesäkuuta 2018

Viimeksi vahvistettu

Maanantai 1. tammikuuta 2018

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Avainsanat

Muita asiaankuuluvia MeSH-ehtoja

Muut tutkimustunnusnumerot

  • 205240 (Rekisterin tunniste: JAPIC-CTI)
  • V72_56 (Muu tunniste: Novartis)
  • 2016-005117-44 (EudraCT-numero)

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa